Inhibition of the proton pump in the parietal cells has been established as the main therapeutic principle in the treatment of acid-related diseases, such as peptic ulcer and gastro-oesophageal reflux. The proton pump inhi bitors are tailored for their purpose. They accumulate in the target cell, are activated by acid and bind strongly to the specific target - the proton pump. The clinical superiority of the proton pump inhibitors is due not only to their high efficacy but also to the long duration of the acid inhibition in comparison with other antisecretory drugs. At present when drug discovery mostly relies on identification and characterization of potential targets by genome research, molecular biology, combinatorial chemistry and automated screening, it seems worthwhile to present the development of the tITst proton pump inhibitor - omeprazol- starting from a chemical structure with an observed antisecretory effect but also severe toxic effects that had to be eliminated. As always, basic and applied research operate luind in hand to optimize the delicate balance be tween efficacy and safety of a new drug. This goal often involves time and many different specialists.
Le informazioni nella sezione "Riassunto" possono far riferimento a edizioni diverse di questo titolo.
The discovery and development of the proton pump inhibitor.- The discovery and development of the proton pump inhibitor.- Mechanism of action.- The gastric H, K ATPase.- Inhibition of the gastric proton pump.- The Pharmacology of proton pump inhibitors.- Inhibition of gastric acid secretion.- Consequences of gastric acid inihibition in animals.- Consequences of gastric acid inhibition in man.- The acid tolerance of Helicobacter pylori.- Interactions of proton pump inhibitors and Helicobacter pylori in vivo.- Comparison of different proton pump inhibitors.- Pharmaceutical considerations.- Pharmaceutical considerations.- Clinical experience with proton pump inhibitors.- Helicobacter pylori infection and peptic ulcer disease.- Non-steroidal anti-inflammatory drug-associated ulcers.- Zollinger-Ellison syndrome.- Gastro-oesophageal reflux disease.- Socio-Economic impact of acid-related diseases.- Socio-economic impact of acid-related diseases.
Le informazioni nella sezione "Su questo libro" possono far riferimento a edizioni diverse di questo titolo.
Da: Basi6 International, Irving, TX, U.S.A.
Condizione: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service. Codice articolo ABEOCT25-406619
Quantità: 1 disponibili
Da: Schätze & Co., Münnerstadt, KG, Germania
Gr. 8°, Hardcover. Condizione: Sehr gut. Ill., 251 S. Sprache: Englisch; sehr gutes Ex. Sprache: Englisch Gewicht in Gramm: 730. Codice articolo 12190
Quantità: 1 disponibili
Da: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Germania
Buch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Inhibition of the proton pump in the parietal cells has been established as the main therapeutic principle in the treatment of acid-related diseases, such as peptic ulcer and gastro-oesophageal reflux. The proton pump inhi bitors are tailored for their purpose. They accumulate in the target cell, are activated by acid and bind strongly to the specific target - the proton pump. The clinical superiority of the proton pump inhibitors is due not only to their high efficacy but also to the long duration of the acid inhibition in comparison with other antisecretory drugs. At present when drug discovery mostly relies on identification and characterization of potential targets by genome research, molecular biology, combinatorial chemistry and automated screening, it seems worthwhile to present the development of the tITst proton pump inhibitor - omeprazol- starting from a chemical structure with an observed antisecretory effect but also severe toxic effects that had to be eliminated. As always, basic and applied research operate luind in hand to optimize the delicate balance be tween efficacy and safety of a new drug. This goal often involves time and many different specialists. 251 pp. Englisch. Codice articolo 9783764358976
Quantità: 2 disponibili
Quantità: Più di 20 disponibili
Da: GreatBookPrices, Columbia, MD, U.S.A.
Condizione: New. Codice articolo 920168-n
Quantità: Più di 20 disponibili
Da: California Books, Miami, FL, U.S.A.
Condizione: New. Codice articolo I-9783764358976
Quantità: Più di 20 disponibili
Da: GreatBookPricesUK, Woodford Green, Regno Unito
Condizione: New. Codice articolo 920168-n
Quantità: Più di 20 disponibili
Da: Ria Christie Collections, Uxbridge, Regno Unito
Condizione: New. In English. Codice articolo ria9783764358976_new
Quantità: Più di 20 disponibili
Da: preigu, Osnabrück, Germania
Buch. Condizione: Neu. Proton Pump Inhibitors | Lars Olbe | Buch | Einband - fest (Hardcover) | Englisch | 1999 | Birkhäuser Basel | EAN 9783764358976 | Verantwortliche Person für die EU: Springer Nature c/o IBS, Benzstr. 21, 48619 Heek, tanja[dot]keller[at]springer[dot]com | Anbieter: preigu Print on Demand. Codice articolo 105259710
Quantità: 5 disponibili
Da: Kennys Bookshop and Art Galleries Ltd., Galway, GY, Irlanda
Condizione: New. This monograph contains a description of the discovery and development of a new antisecretory therapy in the treatment of acid-related diseases: omeprazole, the first pump inhibitor. The pharmacology of different proton pump inhibitors and the pharmaceutic delivery system are reviewed. Editor(s): Olbe, Lars. Series: Milestones in Drug Therapy. Num Pages: 261 pages, biography. BIC Classification: MJH; MMG. Category: (P) Professional & Vocational; (UP) Postgraduate, Research & Scholarly. Dimension: 244 x 170 x 20. Weight in Grams: 730. . 1999. Hardback. . . . . Codice articolo V9783764358976
Quantità: 15 disponibili